Glucagon Related Published Studies
Well-designed clinical trials related to Glucagon
Glucagon-like peptide 1 attenuates the acceleration of gastric emptying induced
by hypoglycemia in healthy subjects. [2014]
Acute effect on satiety, resting energy expenditure, respiratory quotient,
glucagon-like peptide-1, free fatty acids, and glycerol following consumption of
a combination of bioactive food ingredients in overweight subjects. [2013]
Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2
inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide
tyrosine tyrosine in a dose-timing study in healthy subjects. [2013]
The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen. [2011.08]
Glutamine reduces postprandial glycemia and augments the glucagon-like peptide-1 response in type 2 diabetes patients. [2011.07]
A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans. [2011.06]
Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. [2011.05]
Partial inhibition of insulin secretion results in glucose intolerance but not hyperglucagonemia. [2011.04]
Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. [2011.04]
The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients. [2011.03]
The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an "endothelial resistance" to glucagon-like peptide 1 in diabetes. [2011.03]
Additive hypoglycaemic effect of nateglinide and exogenous glucagon-like peptide-1 in type 2 diabetes. [2011.03]
Glucagon-like peptide-2 (GLP-2) increases small intestinal blood flow and mucosal growth in ruminating calves. [2011.02]
Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans. [2011.02]
Effect of feeding fat or intrajugular infusion of glucagon-like peptide-1 and cholecystokinin on dry matter intake, digestibility, and digesta rate of passage in growing wethers. [2011.01]
Individually timing high-protein preloads has no effect on daily energy intake, peptide YY and glucagon-like peptide-1. [2011.01]
Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus. [2011.01]
Exogenous glucagon-like peptide-1 attenuates the glycaemic response to postpyloric nutrient infusion in critically ill patients with type-2 diabetes. [2011]
Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects. [2010.10]
Glucagon suppression during OGTT worsens while suppression during IVGTT sustains alongside development of glucose intolerance in patients with chronic pancreatitis. [2010.09.24]
Chronic metabolic responses of postpartal dairy cows to subcutaneous glucagon injections, oral glycerol, or both. [2010.08]
Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes. [2010.06]
Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease. [2010.06]
Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: relationship to glycemia. [2010.05]
Do the actions of glucagon-like peptide-1 on gastric emptying, appetite, and food intake involve release of amylin in humans? [2010.05]
Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. [2010.04]
Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. [2010.04]
Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. [2010.03]
Role of fat hydrolysis in regulating glucagon-like Peptide-1 secretion. [2010.02]
The effect of glucagon-like peptide-2 on arterial blood flow and cardiac parameters. [2010.01.08]
Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. [2010.01]
Eating slowly increases the postprandial response of the anorexigenic gut hormones, peptide YY and glucagon-like peptide-1. [2010.01]
Adaptation of colonic fermentation and glucagon-like peptide-1 secretion with increased wheat fibre intake for 1 year in hyperinsulinaemic human subjects. [2010.01]
Effects of pre-meal versus post-meal administration of miglitol on plasma glucagon-like peptide-1 and glucosedependent insulinotropic polypeptide levels in healthy men. [2010]
Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food
intake in healthy male subjects. [2010]
Orally administered glucagon-like peptide-1 affects glucose homeostasis following an oral glucose tolerance test in healthy male subjects. [2009.12]
Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. [2009.12]
No increased risk of hypoglycaemic episodes during 48 h of subcutaneous glucagon-like-peptide-1 administration in fasting healthy subjects. [2009.10]
Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study. [2009.07]
Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). [2009.07]
The effects of two different hypocaloric diets on glucagon-like peptide 1 in obese adults, relation with insulin response after weight loss. [2009.07]
Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects. [2009.05]
Effects of 1 and 3 g cinnamon on gastric emptying, satiety, and postprandial blood glucose, insulin, glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and ghrelin concentrations in healthy subjects. [2009.03]
Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects. [2009.02.02]
Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects. [2009.01]
The effect of different protein hydrolysate/carbohydrate mixtures on postprandial glucagon and insulin responses in healthy subjects. [2009.01]
Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study. [2009.01]
The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study. [2009]
Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. [2008.12]
Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects. [2008.09]
Pharmacokinetics and tolerability of a novel long-acting glucagon-like peptide-1 analog, CJC-1131, in healthy and diabetic subjects. [2008.09]
Glucagon-like peptide-1 inhibits blood-brain glucose transfer in humans. [2008.02]
Exogenous glucagon effects on health and reproductive performance of lactating dairy cows with mild fatty liver. [2007.12]
Glucagon-like peptide-1 (7-36) amide response to low versus high glycaemic index preloads in overweight subjects with and without type II diabetes mellitus. [2007.12]
Glucagon-like peptide 1 (GLP-1) suppresses ghrelin levels in humans via increased insulin secretion. [2007.10.04]
Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. [2007.09.01]
Nitrergic contribution to gastric relaxation induced by glucagon-like peptide-1 (GLP-1) in healthy adults. [2007.05]
Single dose glucagon (0.5 mg IV bolus) administration in healthy human volunteers is a robust model for assessment of glycogenolysis: characterisation of the glucose excursion after glucagon challenge. [2007.01]
Comparison of glucagon and scopolamine butylbromide as premedication for colonoscopy in unsedated patients. [2006.09]
Prevention of fatty liver in transition dairy cows by subcutaneous injections of glucagon. [2006.05]
The role of glucagon in regulating chicken hepatic malic enzyme and histidase messenger ribonucleic acid expression in response to an increase in dietary protein intake. [2006.04]
The metabolite generated by dipeptidyl-peptidase 4 metabolism of glucagon-like peptide-1 has no influence on plasma glucose levels in patients with type 2 diabetes. [2006.02]
Effect of octreotide on plasma concentrations of glucose, insulin, glucagon, growth hormone, and cortisol in healthy dogs and dogs with insulinoma. [2006.02]
Ghrelin and glucagon-like peptide 1 concentrations, 24-h satiety, and energy and substrate metabolism during a high-protein diet and measured in a respiration chamber. [2006.01]
Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans. [2006]
Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. [2005.12]
Glucagon-like peptide-1 release and satiety after a nutrient challenge in normal-weight and obese subjects. [2005.06]
The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes. [2005.04]
alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients. [2005.04]
Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. [2004.12]
Effect of pramlintide on symptom, catecholamine, and glucagon responses to hypoglycemia in healthy subjects. [2004.09]
The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. [2004.08]
Additive effects of glucagon-like peptide 1 and pioglitazone in patients with type 2 diabetes. [2004.08]
Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. [2004.06]
Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. [2004.06]
Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. [2004.05]
One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. [2004.05]
Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1. [2004.04.15]
Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes. [2004.03]
Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. [2004.03]
The insulin secretagogues glibenclamide and repaglinide do not influence growth hormone secretion in humans but stimulate glucagon secretion during profound insulin deficiency. [2004.01]
Effects of breakfast with different calorigenic amounts on blood glucose, insulin and glucagon levels. [2003.11]
Recombinant glucagon-like peptide-1 (7-36 amide) lowers fasting serum glucose in a broad spectrum of patients with type 2 diabetes. [2003.10]
Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes. [2003.10]
Absence of a memory effect for the insulinotropic action of glucagon-like peptide 1 (GLP-1) in healthy volunteers. [2003.09]
Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. [2003.06]
No effect of physiological concentrations of glucagon-like peptide-2 on appetite and energy intake in normal weight subjects. [2003.04]
Effect of glucagon-like peptide 1 (7-36 amide) on insulin-mediated glucose uptake in patients with type 1 diabetes. [2003.03]
Differential effects of saturated and monounsaturated fats on postprandial lipemia and glucagon-like peptide 1 responses in patients with type 2 diabetes. [2003.03]
The effect of glucagon-induced gastric relaxation on TLOSR frequency. [2003.02]
Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. [2003.01]
Intravenous glucagon: does it optimize evaluation of the gastrointestinal tract on helical CT? [2002.11]
The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus. [2002.09]
Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals. [2002.09]
The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics. [2002.09]
Plasma glucagon-like peptide-1 (GLP-1) responses to duodenal fat and glucose infusions in lean and obese men. [2002.08]
Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. [2002.08]
The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes. [2002.05]
Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose. [2002.04]
Effects of glucagon-like peptide-1(7-36)amide on motility and sensation of the proximal stomach in humans. [2002.03]
Nasal glucagon delivery using microcrystalline cellulose in healthy volunteers. [2002.02.21]
|
